XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2023 | Mar. 31, 2022
Disaggregation of Revenue [Line Items] |  |
Net sales | $ 4,778 | $ 4,275
United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 3,512 | 3,105
International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 1,266 | 1,170
Other MedSurg and Neurotechnology |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 81 | 69
MedSurg and Neurotechnology: |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 2,690 | 2,423
MedSurg and Neurotechnology: | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 2,033 | 1,799
MedSurg and Neurotechnology: | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 657 | 624
MedSurg and Neurotechnology: | Instruments |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 575 | 528
MedSurg and Neurotechnology: | Instruments | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 450 | 414
MedSurg and Neurotechnology: | Instruments | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 125 | 114
MedSurg and Neurotechnology: | Endoscopy |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 698 | 607
MedSurg and Neurotechnology: | Endoscopy | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 564 | 486
MedSurg and Neurotechnology: | Endoscopy | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 134 | 121
MedSurg and Neurotechnology: | Medical |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 778 | 664
MedSurg and Neurotechnology: | Medical | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 612 | 525
MedSurg and Neurotechnology: | Medical | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 166 | 139
MedSurg and Neurotechnology: | Neurovascular |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 284 | 301
MedSurg and Neurotechnology: | Neurovascular | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 118 | 110
MedSurg and Neurotechnology: | Neurovascular | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 166 | 191
MedSurg and Neurotechnology: | Neuro Cranial |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 355 | 323
MedSurg and Neurotechnology: | Neuro Cranial | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 289 | 264
MedSurg and Neurotechnology: | Neuro Cranial | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 66 | 59
Orthopaedics and Spine: |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 2,088 | 1,852
Orthopaedics and Spine: | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 1,479 | 1,306
Orthopaedics and Spine: | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 609 | 546
Orthopaedics and Spine: | Other |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 94 | 97
Orthopaedics and Spine: | Other | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 61 | 72
Orthopaedics and Spine: | Other | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 33 | 25
Orthopaedics and Spine: | Knees |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 566 | 464
Orthopaedics and Spine: | Knees | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 416 | 345
Orthopaedics and Spine: | Knees | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 150 | 119
Orthopaedics and Spine: | Hips |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 375 | 327
Orthopaedics and Spine: | Hips | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 236 | 202
Orthopaedics and Spine: | Hips | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 139 | 125
Orthopaedics and Spine: | Trauma and Extremities |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 769 | 685
Orthopaedics and Spine: | Trauma and Extremities | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 554 | 487
Orthopaedics and Spine: | Trauma and Extremities | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 215 | 198
Orthopaedics and Spine: | Spine |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 284 | 279
Orthopaedics and Spine: | Spine | United States |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 212 | 200
Orthopaedics and Spine: | Spine | International |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | $ 72 | $ 79

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherMedSurgAndNeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedSurgAndNeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeuroCranialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |